GRACE

cancergrace.org

 

GRACE
E

2020 Highlights on MIBC: What Are the Most Common Risks for Older Adults and How to Assess Them? Is Cisplatin the Backbone Therapy for Older Adult Patients?

By GRACE FEATURING Elizabeth Kessler, Ramy Sedhom
November 13, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

15:52
Lilly

BTK Inhibition for Patients with MCL: Safety and Efficacy Data

Feat. J. Pagel

Featured Video

23:48
Tumor Lysis Syndrome

Strategies for Preventing and Managing Tumor Lysis Syndrome-Associat…

Feat. M. Geyer
Genitourinary
14:25
GRACE

The Role of ctDNA Biomarker in Bladder Cancer

Feat. J. Brown
01:41
GRACE

Immunotherapy Side Effects in Bladder Cancer

Feat. J. Brown
03:29
GRACE

Early vs. Advanced Stage Bladder Cancer Systemic Therapy

Feat. J. Brown
02:39
GRACE

Cisplatin-Based Chemotherapy Regimens for Bladder Cancer

Feat. J. Brown
04:18
GRACE

Cisplatin-Ineligible Treatment Options for Advanced Bladder Cancer

Feat. J. Brown
02:36
GRACE

Avelumab Immunotherapy for Bladder Cancer

Feat. J. Brown
02:11
GRACE

Future Trends for Bladder Cancer Treatment

Feat. J. Brown
08:53
GRACE

Adjuvant Immunotherapy for Bladder Cancer: The IMvigor Trials

Feat. P. Grivas
06:49
GRACE

PD-L1 in Metastatic Bladder Cancer

Feat. J. Brown
15:59
GRACE

2020 Updates on MIBC: Bladder Preservation vs. Radical Cystectomy. W…

Feat. P. Grivas, R. Sedhom
08:49
GRACE

2020 Highlights on MIBC: What Are the Most Common Risks for Older Ad…

Feat. E. Kessler, R. Sedhom
14:38
GRACE

The Role of IO in Bladder Cancer: Potential Benefits in Neoadjuvant …

Feat. E. Plimack, R. Sedhom
17:29
GRACE

Androgen Deprivation Therapy (ADT) in Prostate Cancer: Side Effects …

Feat. R. Sedhom, T. Stewart